Role of cell‐cycle regulators in lung cancer

Lung cancer is the leading cause of cancer death worldwide. Histologically, 80% of lung cancers are classified as non‐small‐cell lung cancer (NSCLC), and the remaining 20% as small‐cell lung cancer (SCLC). Lung carcinoma is the result of molecular changes in the cell, resulting in the deregulation of pathways controlling normal cellular growth, differentiation, and apoptosis. This review summarizes some of the most recent findings about the role of cell‐cycle proteins in lung cancer pathogenesis and progression. © 2005 Wiley‐Liss, Inc.

[1]  E Wolner,et al.  Prognostic value of immunohistochemical expression of p53, bax, Bcl‐2 and Bcl‐xL in resected non‐small‐cell lung cancers , 2004, Histopathology.

[2]  M. Santini,et al.  Analysis of cell cycle regulator proteins in non-small cell lung cancer , 2003, Journal of clinical pathology.

[3]  P. Stiegler,et al.  pRB2/p130 target genes in non-small lung cancer cells identified by microarray analysis , 2003, Oncogene.

[4]  J. Minna,et al.  Lung cancer • 9: Molecular biology of lung cancer: clinical implications , 2003, Thorax.

[5]  S. Singhal,et al.  Differentially Expressed Apoptotic Genes in Early Stage Lung Adenocarcinoma Predicted by Expression Profiling , 2003, Cancer biology & therapy.

[6]  Yusuke Nakamura,et al.  Expression profiles of non-small cell lung cancers on cDNA microarrays: Identification of genes for prediction of lymph-node metastasis and sensitivity to anti-cancer drugs , 2003, Oncogene.

[7]  Sunil Singhal,et al.  Alterations in Cell Cycle Genes in Early Stage Lung Adenocarcinoma Identified by Expression Profiling , 2003, Cancer biology & therapy.

[8]  Avrum Spira,et al.  Gene expression in lung adenocarcinomas of smokers and nonsmokers. , 2003, American journal of respiratory cell and molecular biology.

[9]  David E. Misek,et al.  Overexpression of Oncoprotein 18 Correlates with Poor Differentiation in Lung Adenocarcinomas* , 2003, Molecular & Cellular Proteomics.

[10]  J. Minna,et al.  Loss of expression of death-inducing signaling complex (DISC) components in lung cancer cell lines and the influence of MYC amplification , 2002, Oncogene.

[11]  M. D. Di Marino,et al.  Expression of surface protein receptors in lung cancer. , 2002, Anticancer Research.

[12]  J. Heighway,et al.  Expression profiling of primary non-small cell lung cancer for target identification , 2002, Oncogene.

[13]  F. Kaye,et al.  RB and cyclin dependent kinase pathways: defining a distinction between RB and p16 loss in lung cancer , 2002, Oncogene.

[14]  A. Papavassiliou,et al.  Transcription factor E2F‐1 acts as a growth‐promoting factor and is associated with adverse prognosis in non‐small cell lung carcinomas , 2002, The Journal of pathology.

[15]  H. Wada,et al.  Clinical significance of p21 expression in non-small-cell lung cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  R. K Srivastava,et al.  Role of the phosphatidylinositol 3'-kinase/PTEN/Akt kinase pathway in tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in non-small cell lung cancer cells. , 2002, Cancer research.

[17]  S. Ramaswamy,et al.  Translation of microarray data into clinically relevant cancer diagnostic tests using gene expression ratios in lung cancer and mesothelioma. , 2002, Cancer research.

[18]  David E. Misek,et al.  Gene-expression profiles predict survival of patients with lung adenocarcinoma , 2002, Nature Medicine.

[19]  L. Liotta,et al.  Laser capture microdissection and microarray expression analysis of lung adenocarcinoma reveals tobacco smoking- and prognosis-related molecular profiles. , 2002, Cancer research.

[20]  M. Tyers,et al.  Molecular profiling of non-small cell lung cancer and correlation with disease-free survival. , 2002, Cancer research.

[21]  M. Marton,et al.  Identification of genes over-expressed in small cell lung carcinoma using suppression subtractive hybridization and cDNA microarray expression analysis , 2002, Oncogene.

[22]  Shigeki Shimizu,et al.  [Molecular abnormalities in lung cancer]. , 2002, Nihon rinsho. Japanese journal of clinical medicine.

[23]  E. Brambilla,et al.  Mdm2 overexpression and p14ARF inactivation are two mutually exclusive events in primary human lung tumors , 2002, Oncogene.

[24]  É. Szabó,et al.  Enhanced growth inhibition by combination differentiation therapy with ligands of peroxisome proliferator-activated receptor-gamma and inhibitors of histone deacetylase in adenocarcinoma of the lung. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[25]  David E. Misek,et al.  Discordant Protein and mRNA Expression in Lung Adenocarcinomas * , 2002, Molecular & Cellular Proteomics.

[26]  Carl W. Miller,et al.  Mutations of the CHK2 gene are found in some osteosarcomas, but are rare in breast, lung, and ovarian tumors , 2002, Genes, chromosomes & cancer.

[27]  Michael Ruogu Zhang,et al.  Molecular characteristics of non-small cell lung cancer , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[28]  D. Botstein,et al.  Diversity of gene expression in adenocarcinoma of the lung , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[29]  K. Nagashima,et al.  Cyclin D1, p16 and retinoblastoma gene product expression as a predictor for prognosis in non-small cell lung cancer at stages I and II. , 2001, Lung cancer.

[30]  S. Hajdu,et al.  Gene expression patterns of paired bronchioloalveolar carcinoma and benign lung tissue. , 2001, Annals of clinical and laboratory science.

[31]  D. Harpole,et al.  Predicting the sites of metastases from lung cancer using molecular biologic markers. , 2001, The Annals of thoracic surgery.

[32]  S. Elledge,et al.  Reduced expression and impaired kinase activity of a Chk2 mutant identified in human lung cancer. , 2001, Cancer research.

[33]  R. Kratzke,et al.  Mechanisms of G1 checkpoint loss in resected early stage non-small cell lung cancer. , 2001, Lung cancer.

[34]  A. Yamauchi,et al.  E-cadherin expression associated with differentiation and prognosis in patients with non-small cell lung cancer. , 2001, The Annals of thoracic surgery.

[35]  T. Mitsudomi,et al.  Prognostic significance of p53 alterations in patients with non-small cell lung cancer: a meta-analysis. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[36]  A. Baldi,et al.  Expression of p21 in non small cell lung cancer relationship with PCNA. , 2000, Anticancer research.

[37]  F. Khuri,et al.  Overexpression of cyclin B1 in early-stage non-small cell lung cancer and its clinical implication. , 2000, Cancer research.

[38]  V. Godfrey,et al.  Functional Collaboration between Different Cyclin-Dependent Kinase Inhibitors Suppresses Tumor Growth with Distinct Tissue Specificity , 2000, Molecular and Cellular Biology.

[39]  N. Mailand,et al.  Rapid destruction of human Cdc25A in response to DNA damage. , 2000, Science.

[40]  K. Yanagisawa,et al.  Heterogeneities in the biological and biochemical functions of Smad2 and Smad4 mutants naturally occurring in human lung cancers , 2000, Oncogene.

[41]  S. Chi,et al.  Loss of imprinting and elevated expression of wild-type p73 in human gastric adenocarcinoma. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[42]  D. Harpole,et al.  Molecular biologic substaging of stage I lung cancer according to gender and histology. , 2000, The Annals of thoracic surgery.

[43]  J. Minna,et al.  Mutations in the retinoblastoma-related gene RB2/p130 in lung tumors and suppression of tumor growth in vivo by retrovirus-mediated gene transfer. , 2000, Cancer research.

[44]  B. A. M. Groegera,et al.  INDEPENDENT PROGNOSTIC ROLE OF p16 EXPRESSION IN LUNG CANCER , 1999 .

[45]  J. H. Lee,et al.  Cyclin D1 overexpression is an indicator of poor prognosis in resectable non-small cell lung cancer , 1999, British Journal of Cancer.

[46]  M. Herlyn,et al.  Induction of p21WAF1/CIP1and Inhibition of Cdk2 Mediated by the Tumor Suppressor p16INK4a , 1999, Molecular and Cellular Biology.

[47]  Y. Nishiwaki,et al.  Prognostic factors in clinical stage I non-small cell lung cancer. , 1999, The Annals of thoracic surgery.

[48]  D. Harpole,et al.  A biologic risk model for stage I lung cancer: immunohistochemical analysis of 408 patients with the use of ten molecular markers. , 1999, The Journal of thoracic and cardiovascular surgery.

[49]  E. Lees,et al.  Cyclin D-CDK Subunit Arrangement Is Dependent on the Availability of Competing INK4 and p21 Class Inhibitors , 1999, Molecular and Cellular Biology.

[50]  D. Tindall,et al.  Overexpression of the wild type p73 gene in human bladder cancer , 1999, Oncogene.

[51]  M. Tschan,et al.  Expression of p16INK4a/p16α and p19ARF/p16β is frequently altered in non-small cell lung cancer and correlates with p53 overexpression , 1998, Oncogene.

[52]  S. Jiang,et al.  Active cyclin A-CDK2 complex, a possible critical factor for cell proliferation in human primary lung carcinomas. , 1998, The American journal of pathology.

[53]  D. Kirsch,et al.  Tumor-suppressor p53: implications for tumor development and prognosis. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[54]  M. Kitagawa,et al.  Role of p27Kip1 and cyclin-dependent kinase 2 in the proliferation of non-small cell lung cancer. , 1998, The American journal of pathology.

[55]  T. Nakajima,et al.  Correlation between methylation status of the p16/CDKN2 gene and the expression of p16 and Rb proteins in primary non‐small cell lung cancers , 1998, International journal of cancer.

[56]  S. Miyoshi,et al.  Disruption of the RB pathway and cell‐proliferative activity in non‐small‐cell lung cancers , 1998, International journal of cancer.

[57]  Y. Yatabe,et al.  p27KIP1 in human lung cancers: differential changes in small cell and non-small cell carcinomas. , 1998, Cancer research.

[58]  A. Giordano,et al.  p21waf1/cip1mda-6 expression in non-small-cell lung cancer: relationship to survival. , 1998, American journal of respiratory cell and molecular biology.

[59]  V. Gouyer,et al.  Mechanism of retinoblastoma gene inactivation in the spectrum of neuroendocrine lung tumors. , 1998, American journal of respiratory cell and molecular biology.

[60]  V. Gouyer,et al.  Mechanisms of p16INK4A inactivation in non small-cell lung cancers , 1998, Oncogene.

[61]  A. Marchetti,et al.  Cyclin D1 and retinoblastoma susceptibility gene alterations in non‐small cell lung cancer , 1998, International journal of cancer.

[62]  M L Agarwal,et al.  The p53 Network* , 1998, The Journal of Biological Chemistry.

[63]  C. D. Edwards,et al.  p16INK4A Participates in a G1 Arrest Checkpoint in Response to DNA Damage , 1998, Molecular and Cellular Biology.

[64]  D. Warburton,et al.  Cyclin D1 antisense RNA destabilizes pRb and retards lung cancer cell growth. , 1997, American journal of physiology. Lung cellular and molecular physiology.

[65]  A. Giordano,et al.  Differential expression of Rb2/p130 and p107 in normal human tissues and in primary lung cancer. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[66]  Esposito,et al.  Prognostic role of the cyclin-dependent kinase inhibitor p27 in non-small cell lung cancer. , 1997, Cancer research.

[67]  N. Tommerup,et al.  Loss of the retinoblastoma protein-related p130 protein in small cell lung carcinoma. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[68]  A. Giordano,et al.  Prognostic value of p53 in non-small cell lung cancer: relationship with proliferating cell nuclear antigen and cigarette smoking. , 1997, Human pathology.

[69]  C. Sherr.  Cancer Cell Cycles , 1996, Science.

[70]  A. Giordano,et al.  Retinoblastoma protein family in cell cycle and cancer: A review , 1996, Journal of cellular biochemistry.

[71]  A. Giordano,et al.  Differential expression of the retinoblastoma gene family members pRb/p105, p107, and pRb2/p130 in lung cancer. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[72]  N. Bleehen,et al.  Expression of apoptosis-regulatory genes in lung tumour cell lines: relationship to p53 expression and relevance to acquired drug resistance. , 1996, British Journal of Cancer.

[73]  A. Okamoto,et al.  Intragenic mutations of the p16INK4, p15INK4B and p18 genes in primary non‐small‐cell lung cancers , 1996 .

[74]  Carl W. Miller,et al.  Molecular analysis of a family of cyclin‐dependent kinase inhibitor genes (p15/MTS2/INK4b and p18/INK4c) in non‐small cell lung cancers , 1995, Molecular carcinogenesis.

[75]  D. Shopland.  Tobacco use and its contribution to early cancer mortality with a special emphasis on cigarette smoking. , 1995, Environmental health perspectives.

[76]  N. Goldstein,et al.  Cell cycle gene expression and E2F transcription factor complexes in human melanoma cells induced to terminally differentiate. , 1995, Oncogene.

[77]  D. Harpole,et al.  Stage I nonsmall cell lung cancer. A multivariate analysis of treatment methods and patterns of recurrence , 1995, Cancer.

[78]  L. J. Veer,et al.  E2F-5, a new E2F family member that interacts with p130 in vivo , 1995, Molecular and cellular biology.

[79]  D. Livingston,et al.  Functional interaction between E2F-4 and p130: evidence for distinct mechanisms underlying growth suppression by different retinoblastoma protein family members. , 1995, Genes & development.

[80]  E. Lam,et al.  DP and E2F proteins: coordinating transcription with cell cycle progression. , 1994, Current opinion in cell biology.

[81]  G. Condorelli,et al.  p130/pRb2 has growth suppressive properties similar to yet distinctive from those of retinoblastoma family members pRb and p107. , 1994, Cancer research.

[82]  J. Minna,et al.  Molecular pathogenesis of lung cancer. , 1994, Annual review of physiology.

[83]  G. Hannon,et al.  Differential effects by the p21 CDK inhibitor on PCNA-dependent DNA replication and repair , 1994, Nature.

[84]  M. Higashiyama,et al.  Retinoblastoma protein expression in lung cancer: an immunohistochemical analysis. , 1994, Oncology.

[85]  G. Hannon,et al.  The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA , 1994, Nature.

[86]  R. Weinberg,et al.  Cell cycle-specific association of E2F with the p130 E1A-binding protein. , 1993, Genes & development.

[87]  A. Giordano,et al.  Cloning of a new member of the retinoblastoma gene family (pRb2) which binds to the E1A transforming domain. , 1993, Oncogene.

[88]  M. Ewen,et al.  Inhibition of cell proliferation by p107, a relative of the retinoblastoma protein. , 1993, Genes & development.

[89]  M. Ewen,et al.  The transcription factor E2F interacts with the retinoblastoma product and a p107-cyclin A complex in a cell cycle-regulated manner , 1992, Cell.

[90]  M. Ewen,et al.  Molecular cloning, chromosomal mapping, and expression of the cDNA for p107, a retinoblastoma gene product-related protein , 1991, Cell.

[91]  R. Bravo,et al.  Cyclin/PCNA is the auxiliary protein of DNA polymerase-δ , 1987, Nature.

[92]  B. Stillman,et al.  Functional identity of proliferating cell nuclear antigen and a DNA polymerase-δ auxiliary protein , 1987, Nature.

[93]  L. Rubinstein,et al.  Sites of recurrence in resected stage I non-small-cell lung cancer: a guide for future studies. , 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[94]  G. Condorelli,et al.  Advances in Brief p 130 / pRb 2 Has Growth Suppressive Properties Similar to yet Distinctive from Those of Retinoblastoma Family Members pRb and p 107 ' , 2006 .

[95]  Y. Yatabe,et al.  p 27 KIP 1 in Human Lung Cancers : Differential Changes in Small Cell and Non-Small Cell Carcinomas 1 , 2006 .

[96]  J. Gu,et al.  Induction of p53-regulated genes and tumor regression in lung cancer patients after intratumoral delivery of adenoviral p53 (INGN 201) and radiation therapy. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[97]  P. Stiegler,et al.  RB2/p130 gene-enhanced expression down-regulates vascular endothelial growth factor expression and inhibits angiogenesis in vivo. , 2001, Cancer research.

[98]  S. Milligan,et al.  Inhibition of NF-kappa B with proteasome inhibitors enhances apoptosis in human lung adenocarcinoma cells in vitro. , 2001, Anticancer research.

[99]  E. Lander,et al.  Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[100]  T. Mitsudomi,et al.  Prognostic Significance of p 53 Alterations in Patients with Non-Small Cell Lung Cancer : A Meta-Analysis 1 , 2000 .

[101]  G. C. Nogueira,et al.  Stages I and II , 2000 .

[102]  M. Bibbo,et al.  The role of pRb2/p130 protein in diagnosing lung carcinoma on fine needle aspiration biopsies. , 1999, Pathology, research and practice.

[103]  M. Volm,et al.  Cyclin A is associated with an unfavourable outcome in patients with non-small-cell lung carcinomas. , 1997, British Journal of Cancer.

[104]  D. Warburton,et al.  Cyclin D 1 antisense RNA destabilizes pRb and retards lung cancer cell growth , 1997 .

[105]  A. Giordano,et al.  Cyclins, cyclin-dependent kinases and cdk inhibitors: implications in cell cycle control and cancer. , 1995, Critical reviews in eukaryotic gene expression.